Results 31 to 40 of about 740,069 (270)

Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age [PDF]

open access: yesCancer, 2010
Cisplatin and carboplatin are essential to management of advanced-stage epithelial ovarian carcinoma. No published data exist regarding carboplatin dose intensity importance in ovarian cancer, nor are there data for the effect of age on the ability to deliver dose-intensive carboplatin.Retrospective dose intensity analyses were performed for 93 ...
T L, Cornelison, E, Reed
openaire   +2 more sources

The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer

open access: yesBMC Cancer, 2022
Background An uninterrupted dose of oxaliplatin-based cytotoxic therapy is an essential component in the standard treatment regimen of metastatic colon cancer (mCC). Data on the impacts of dose intensity reduction on the palliative treatment for patients
Mohd Naqib Zainal Abidin   +3 more
doaj   +1 more source

Commissioning and Evaluation of an Electronic Portal Imaging Device-Based In-Vivo Dosimetry Software. [PDF]

open access: yes, 2018
This study reports on our experience with the in-vivo dose verification software, EPIgray® (DOSIsoft, Cachan, France). After the initial commissioning process, clinical experiments on phantom treatments were evaluated to assess the level of accuracy of ...
Cheung, Joey   +4 more
core   +2 more sources

Nutritional status predicts adjuvant chemotherapy outcomes for stage III colorectal cancer

open access: yesJournal of the Anus, Rectum and Colon, 2019
Objectives: Previously, adjuvant chemotherapy using oxaliplatin was a standard treatment for patients with node-positive colorectal cancer (CRC) who underwent curative surgery. The factor predicting adverse events and therapeutic effect have not yet been
Keisuke Ihara   +10 more
doaj   +1 more source

Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer. [PDF]

open access: yesCancer Chemother Pharmacol
Quantifying the association of chemotherapy relative dose intensity (RDI) with overall survival may enable supportive care interventions that improve chemotherapy RDI to estimate their magnitude of potential clinical benefit.This cohort study included 533 patients with stage II-III colon cancer who initiated a planned regimen of 12 cycles of 5 ...
Brown JC   +3 more
europepmc   +3 more sources

Exercise during chemotherapy: Friend or foe?

open access: yesCancer Medicine, 2023
Background A higher chemotherapy completion rate is associated with better outcomes including treatment efficacy and overall survival. Exercise may have the potential to improve relative dose intensity (RDI) by reducing the frequency and severity of ...
Melanie Potiaumpai   +5 more
doaj   +1 more source

Accurate,robust and harmonized implementation of morpho-functional imaging in treatment planning for personalized radiotherapy [PDF]

open access: yes, 2019
In this work we present a methodology able to use harmonized PET/CT imaging in dose painting by number (DPBN) approach by means of a robust and accurate treatment planning system.
Baeza, José Antonio   +8 more
core   +2 more sources

Effects of pre-exercise carbohydrate consumption on metabolism during exercise [PDF]

open access: yes, 2016
It is well documented that consuming carbohydrates (CHO) prior to exercise has been shown to alter metabolism. There are many ways that CHO ingestion affects substrate utilization and blood glucose dynamics at the start of exercise.
Montzingo, Luke James
core   +1 more source

Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia

open access: yesCurrent Oncology, 2023
We investigated the impact of sarcopenia on adjuvant chemotherapy dosing in advanced epithelial ovarian cancer (EOC). The chemotherapy dosing and toxicity of 173 eligible patients who underwent cytoreductive surgery and adjuvant chemotherapy at a single ...
Rushi Shah   +4 more
doaj   +1 more source

Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics [PDF]

open access: yes, 2019
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR ...
Beattie, Bradley J.   +10 more
core   +2 more sources

Home - About - Disclaimer - Privacy